Physician profile
Hillard M Lazarus
NPI 1255351920
$2,044,799.58
in general payments reported to CMS, 2019-2025
19 companies · $103K in 2025
The $103K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234K · 2020: $281K · 2021: $366K · 2022: $375K · 2023: $363K · 2024: $322K · 2025: $103K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $631K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $136K · Travel and Lodging: $18K · Food and Beverage: $2,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $630,867.38 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $135,991.99 |
| Travel and Lodging | $17,942.81 |
| Food and Beverage | $2,936.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Partner Therapeutics, INC. | $1,416,870.48 | 2020-2025 | Leukine |
| Seagen INC. | $179,940.75 | 2019-2023 | Adcetris |
| Jazz Pharmaceuticals INC. | $157,219.39 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $72,997.14 | 2019-2025 | Reblozyl |
| Celgene Corporation | $43,147.58 | 2019-2022 | |
| Amgen INC. | $41,199.51 | 2024-2025 | Blincyto, Blincyto |
| Astrazeneca Pharmaceuticals Lp | $35,076.26 | 2019-2022 | |
| Csl Behring | $23,785.28 | 2020-2023 | Hizentra, Privigen |
| Pfizer INC. | $18,638.84 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $17,219.90 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $16,760.77 | 2019 | |
| Genentech USA, INC. | $7,653.84 | 2019 | |
| Alexion Pharmaceuticals, INC. | $5,333.38 | 2024 | Ultomiris |
| Janssen Biotech, INC. | $2,823.93 | 2019 | |
| Kadmon Pharmaceuticals LLC | $2,516.25 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,965.00 | 2019 | |
| Genzyme Corporation | $1,300.00 | 2020 | |
| Kite Pharma, INC. | $252.28 | 2019-2020 | |
| Astellas Pharma US INC | $99.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hillard Lazarus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.